![]() | |
Clinical data | |
---|---|
Trade names | Vtama, others |
Other names | Benvitimod; GSK-2894512; (E)-3,5-Dihydroxy-4-isopropyl-trans-stilbene; 3,5-Dihydroxy-4-isopropylstilbene |
License data | |
Routes of administration | Topical |
Drug class | Aryl hydrocarbon receptor agonist |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H18O2 |
Molar mass | 254.329 g·mol−1 |
3D model (JSmol) | |
| |
|
Tapinarof, also known as benvitimod and sold under the brand name Vtama among others, is a medication used for the treatment of plaque psoriasis. [3] The medication is applied to the skin. [3] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [4] [5]
The medication acts as an aryl hydrocarbon receptor agonist. [3] [6]
Tapinarof was approved for medical use in the United States in May 2022. [3] [7] [8] [9] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [10] [11]
Tapinarof is indicated for the treatment of plaque psoriasis in adults. [3]
In case of short term use the most common adverse effects are folliculitis, contact dermatitis, headache, pruritus (itching), and upper respiratory tract infection. [12] [13]
Tapinarof binds directly to topical aryl hydrocarbon receptor (AhR), suppressing inflammatory cytokines, modulating skin barrier protein expression, reducing oxidative stress, and regulating gene expression in immune cells. [14] [15] [16]
Tapinarof 1% cream once daily was superior to vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks and having a favorable safety profile in the treatment of psoriatic patients. [12] [17]
Tapinarof, also known as benvitimod and sold under the brand name Vtama, is a medication used for the treatment of plaque psoriasis. [3] The medication is applied to the skin. [3] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [4] [5]
The medication acts as an aryl hydrocarbon receptor agonist. [3] [6] Tapinarof was approved for medical use in the United States in May 2022. [3] [7] [8] [9] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [10]
Tapinarof is the international nonproprietary name. [18]
Tapinarof, also known as benvitimod, is a bacterial stilbenoid produced in Photorhabdus bacterial symbionts of Heterorhabditis nematodes. It is a product of an alternative ketosynthase-directed stilbenoid biosynthesis pathway. It is derived from the condensation of two β-ketoacyl thioesters. [4] It is produced by the Photorhabdus luminescens bacterial symbiont species of the entomopathogenic nematode, Heterorhabditis megidis . Experiments with infected larvae of Galleria mellonella , the wax moth, support the hypothesis that the compound has antibiotic properties that help minimize competition from other microorganisms and prevents the putrefaction of the nematode-infected insect cadaver. [5]